NAGE
Niagen Bioscience Inc.

3,451
Mkt Cap
$524.33M
Volume
648,072.00
52W High
$14.69
52W Low
$5.17
PE Ratio
26.95
NAGE Fundamentals
Price
$6.56
Prev Close
$6.57
Open
$6.54
50D MA
$6.74
Beta
1.42
Avg. Volume
770,180.05
EPS (Annual)
$0.1094
P/B
7.39
Rev/Employee
$957,663.46
Loading...
Loading...
News
all
press releases
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are covering the firm, Marketbeat reports. One...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Precision Wealth Strategies LLC Makes New $1.53 Million Investment in Niagen Bioscience, Inc. $NAGE
Precision Wealth Strategies LLC bought a new stake in Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) in the third quarter, according to the company in its most recent 13F filing with the...
MarketBeat·14d ago
News Placeholder
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queens University Belfast
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has acquired a...
Business Wire·18d ago
News Placeholder
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Moderate Buy" from Brokerages
Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat...
MarketBeat·29d ago
News Placeholder
Niagen Bioscience (NASDAQ:NAGE) CFO Acquires 4,465 Shares
Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) CFO Ozan Pamir bought 4,465 shares of the stock in a transaction dated Friday, November 14th. The stock was bought at an average price of $6.81...
MarketBeat·2mo ago
News Placeholder
Niagen Bioscience Launches Tru Niagen Beauty The First NAD+ Skincare Supplement in the U.S. Featuring Niagen (Patented Nicotinamide Riboside)
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Tru Niagen Beauty...
Business Wire·2mo ago
News Placeholder
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the...
Business Wire·2mo ago
News Placeholder
Q2 EPS Estimate for Niagen Bioscience Raised by Analyst
Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Research analysts at Roth Capital raised their Q2 2026 EPS estimates for shares of Niagen Bioscience in a research note issued to investors on...
MarketBeat·2mo ago
News Placeholder
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up After Better-Than-Expected Earnings
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up on Earnings Beat...
MarketBeat·2mo ago
News Placeholder
Niagen Bioscience Announces $10 Million Share Repurchase Program
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has...
Business Wire·2mo ago
<
1
2
...
>

Latest NAGE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.